Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug
By Elias Schisgall
Shares of Context Therapeutics rose after the Food and Drug Administration moved to expedite its review of the biopharmaceutical company's treatment for ovarian cancer.
The stock climbed 8.7% to $2.88 midday Thursday. The stock has nearly doubled in value year to date.
The drug to receive Fast Track Designation, CTIM-76, is currently being evaluated in a Phase 1 trial to evaluate its safety and efficacy in patients with ovarian, endometrial, or testicular cancers, Context said.
The FDA's designation, which is designed to speed the development of treatments for serious conditions in areas of unmet need, applies to CTIM-76 for the treatment of platinum-resistant ovarian cancer.
"This designation is an important step forward in our goal to quickly and efficiently advance CTIM-76 through clinical development and we look forward to sharing interim data for this program in June 2026," Context Chief Medical Officer Karen Chagin said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
April 02, 2026 12:12 ET (16:12 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States